Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients
- 1 May 2008
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Pharmacogenetics and Genomics
- Vol. 18 (5), 413-423
- https://doi.org/10.1097/fpc.0b013e3282f9ac01
Abstract
Objective The potential influence of the multidrug resistance 1 (MDR1) gene and the cytochrome P450 (CYP) genes, CYP3A4 and CYP3A5, on the oral clearance (CL/F) of tacrolimus in adult living-donor liver transplant patients was examined. Furthermore, the development of renal dysfunction was analyzed in relation to the CYP3A5 genotype. Methods Sixty de novo adult liver transplant patients receiving tacrolimus were enrolled in this study. The effects of various covariates (including intestinal and hepatic mRNA levels of MDR1 and CYP3A4, measured in each tissue taken at the time of transplantation, and the CYP3A5*3 polymorphism) on CL/F during the first 50 days after surgery were investigated with the nonlinear mixed-effects modeling program. Results CL/F increased linearly until postoperative day 14, and thereafter reached a steady state. The initial CL/F immediately after liver transplantation was significantly affected by the intestinal MDR1 mRNA level (PCYP3A5*1 allele in the native intestine, but not in the graft liver, showed a 1.47 times higher (95% confidence interval, 1.17–1.77 times, PCYP3A5*3/*3 genotype. The cumulative incidence of renal dysfunction within 1 year after transplantation, evaluated by the Kaplan–Meier method, was significantly associated with the recipient's but not donor's CYP3A5 genotype (*1/*1 and *1/*3 vs. *3/*3: recipient, 17 vs. 46%, PP=0.81). Conclusion These findings suggest that the CYP3A5*1 genotype as well as the MDR1 mRNA level in enterocytes contributes to interindividual variation in the CL/F of tacrolimus in adult recipients early after living-donor liver transplantation. Furthermore, CYP3A5 in the kidney may play a protective role in the development of tacrolimus-related nephrotoxicity.Keywords
This publication has 47 references indexed in Scilit:
- Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patientsBritish Journal of Clinical Pharmacology, 2007
- An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patientsPharmacology & Therapeutics, 2006
- Living-donor liver transplantation: an overviewJournal of Hepato-Biliary-Pancreatic Surgery, 2006
- Tacrolimus dose requirement in relation to donor and recipientABCB1 andCYP3A5 gene polymorphisms in Chinese liver transplant patientsLiver Transplantation, 2006
- Sirolimus Population Pharmacokinetic/Pharmacogenetic Analysis and Bayesian Modelling in Kidney Transplant RecipientsClinical Pharmacokinetics, 2006
- Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitorsPharmacogenetics, 2003
- Small-for-size grafts in living-related liver transplantationJournal of the American College of Surgeons, 2001
- Covariate Effects on the Apparent Clearance of Tacrolimus in Paediatric Liver Transplant Patients Undergoing Conversion TherapyClinical Pharmacokinetics, 2001
- Effects of the Antifungal Agents on Oxidative Drug MetabolismClinical Pharmacokinetics, 2000
- Clinical Pharmacokinetics of TacrolimusClinical Pharmacokinetics, 1995